公开(公告)号：US20240025884A1

公开(公告)日：2024-01-25

申请号：US17857706

申请日：2022-07-05

申请人： Dong-A ST Co., Ltd.

发明人： Cheonhyoung Park ,  Kimoon Ryu ,  Tae-Hun Kim ,  Ha Yoon Kim ,  Eunhye Ju ,  Hyung Ki Lee ,  Youngjee Jeong ,  Doyoung Choi ,  Jun Hwan Moon ,  Nayeon Park ,  Iksoo Jang ,  Kyu Hwan Kim ,  Hyangsoo Lee ,  Min Jung Lee

IPC分类号： C07D403/14 ,  A61K31/506 ,  A61K31/53 ,  A61K31/5377 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  A61K31/541 ,  C07D409/14 ,  C07D471/04 ,  A61P35/00

CPC分类号： C07D403/14 ,  A61K31/506 ,  A61K31/53 ,  A61K31/5377 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  A61K31/541 ,  C07D409/14 ,  C07D471/04 ,  A61P35/00

摘要： Provided herein are novel compounds, e.g., those of Formula (I), as GCN2 inhibitors. Also provided are pharmaceutical compositions including one or more of the novel compounds, and pharmaceutical uses thereof. Compounds provided herein can typically inhibit an activity of a GCN2 and thus can be used for treating or preventing diseases related thereto.

公开(公告)号：US20230143119A1

公开(公告)日：2023-05-11

申请号：US17905918

申请日：2021-03-10

申请人： DONG-A ST CO., LTD.

发明人： Mi-Kyung KIM ,  Tae Hyoung KIM ,  Il Hoon JUNG ,  Yu Na CHAE ,  Jae Sung YANG

IPC分类号： A61K31/506 ,  A61K31/4985 ,  A61K31/495 ,  A61K31/351 ,  A61K31/64 ,  A61K31/192 ,  A61K31/155 ,  A61K31/133 ,  A61P3/10

CPC分类号： A61K31/506 ,  A61K31/4985 ,  A61K31/495 ,  A61K31/351 ,  A61K31/64 ,  A61K31/192 ,  A61K31/155 ,  A61K31/133 ,  A61P3/10

摘要： The present invention relates to a pharmaceutical composite composition for prevention or treatment of diabetes mellitus and at least one disease selected from metabolic diseases associated therewith. The pharmaceutical composition according to the present invention exhibits excellent effects of lowering blood glucose levels, body weight, and blood lipid levels. Therefore, the composition can be advantageously used for preventing or treating diabetes mellitus and at least one disease selected from metabolic diseases associated therewith.

公开(公告)号：US11236142B2

公开(公告)日：2022-02-01

申请号：US16638970

申请日：2018-08-16

申请人： DONG-A ST CO., LTD.

发明人： Jae-Sung Yang ,  Kyung-Seok Lee ,  Yu-Na Chae ,  Gye-Rim Baek ,  Tae-Hyoung Kim ,  Ill-Hun Jung ,  Chae-Lim Ryu ,  Weon-Bin Im

IPC分类号： A61K38/00 ,  C07K14/575 ,  A61P3/04 ,  A61P3/10

摘要： The present invention relates to a novel peptide analog of acylated oxyntomodulin and a pharmaceutical composition comprising the same for preventing and treating obesity or overweightness, or diabetes accompanied by obesity and overweightness. The peptides are superior to those of natural oxyntomodulin in dual agonism on GLP-1 and glucagon receptors and longer in vivo half-life. A pharmaceutical composition comprising said peptides is effective in the treatment of metabolic diseases such as obesity and diabetes mellitus.

公开(公告)号：US20210121449A1

公开(公告)日：2021-04-29

申请号：US16895816

申请日：2020-06-08

申请人： Dong-A St Co., Ltd.

发明人： Jae K. Rhee ,  Weon B. Im ,  Chong H. Cho ,  Sung H. Choi ,  Tae H. Lee

IPC分类号： A61K31/4439 ,  C07D263/32 ,  C07D417/10 ,  C07D417/14 ,  C07F9/653 ,  C07D413/14 ,  C07F9/6558 ,  A61K31/675

摘要： The present invention relates to novel derivatives of oxazolidinone, a method thereof and pharmaceutical compositions comprising the derivatives for use in an antibiotic. The oxazolidinone derivatives of the present invention show inhibitory activity against a broad spectrum of bacteria and lower toxicity. The prodrugs, prepared by reacting the compound having hydroxyl group with amino acid or phosphate, have an excellent efficiency on solubility thereof against water. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi, anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium. Accordingly, the compositions comprising the oxazolidinone are used in an antibiotic.

公开(公告)号：US10813973B2

公开(公告)日：2020-10-27

申请号：US15484067

申请日：2017-04-10

申请人： DONG-A ST CO., LTD.

发明人： Soon-Hoe Kim ,  Mi-Won Son ,  Sang-Zin Choi ,  Hye-Ju Kim ,  Ja-Young Ryu ,  Sun-Yeou Kim

IPC分类号： A61K36/8945 ,  A23L33/105 ,  A23L2/52 ,  A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48

摘要： Disclosed are a pharmaceutical composition and a health functional food for the prevention and treatment of diabetic peripheral neuropathy, comprising an herb extract of a mixture of 3.5:1 Dioscorea Rhizoma:Dioscorea nipponica (w/w). Having the ability to synergistically increase in vivo levels of nerve growth factor, compared to the extracts from the herbs alone or herb mixtures of other weight ratios, the mixed herb extract is effective for preventing the apoptosis of nerve cells and promoting nerve regeneration. Thus, it can be applied to pharmaceutical compositions and health functional foods preventive and curative of diabetic peripheral neuropathy.

公开(公告)号：US10709752B2

公开(公告)日：2020-07-14

申请号：US15484034

申请日：2017-04-10

申请人： DONG-A ST CO., LTD.

发明人： Soon-Hoe Kim ,  Mi-Won Son ,  Sang-Zin Choi ,  Hye-Ju Kim ,  Ja-Young Ryu ,  Sun-Yeou Kim

IPC分类号： A61K36/8945 ,  A23L33/105 ,  A23L2/52 ,  A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48

摘要： This invention relates to a pharmaceutical composition and a health functional food for preventing or improving neurodegenerative disorders comprising mixed herb extracts of Dioscorea Rhizoma and Dioscorea nipponica in a weight ratio of 3.5:1 (w/w). The herb extracts mixed Dioscorea Rhizoma and Dioscorea nipponica in a weight ratio of 3.5:1 have the synergetic effects on increasing the amount of nerve growth factor in vivo, increasing the neural cell proliferation, promoting the formation of neuritis and enhancing cognitive abilities. Thus, the herb extracts of the present invention may be used for a pharmaceutical composition and a health functional food for preventing or treating neurodegenerative disorders.

公开(公告)号：US09809583B2

公开(公告)日：2017-11-07

申请号：US15305929

申请日：2015-04-07

申请人： DONG-A ST CO., LTD.

发明人： Sung Pil Choi ,  Seul Min Choi ,  Byoung Hwa Son ,  Hyun Jung Kim ,  Ju Mi Kim ,  Byung Jun Jang ,  Ji Hyun Sung ,  Ji Hye Lee ,  Eunjin Kim ,  Kyung Koo Kang ,  Soon-Hoe Kim

IPC分类号： C07D413/12 ,  C07D413/06 ,  C07D263/04 ,  C07D263/06 ,  A61K31/421

CPC分类号： C07D413/12 ,  A61K31/421 ,  C07D263/04 ,  C07D263/06 ,  C07D413/06

摘要： Provided are novel selective androgen receptor agonists, a preparation method thereof, and a pharmaceutical composition including the same at a pharmaceutically effective amount. The selective androgen receptor agonists according to the present invention act on androgen receptors to increase androgen activity, thereby being usefully applied as a therapeutic and prophylactic agent for diseases or conditions, of which symptoms may be improved or may respond to treatment by increased activities of androgen receptors, namely, a variety of hormone-related diseases in male and female, muscle wasting disorders, osteoporosis, etc.

公开(公告)号：US20160168167A1

公开(公告)日：2016-06-16

申请号：US14908006

申请日：2014-07-28

申请人： DONG-A ST CO., LTD.

发明人： Soon-Hoe Kim ,  Weon-Bin Im ,  Seung-Bum Ha ,  Jung-Sang Park ,  Mi-Yeon Kim ,  Sung-Hak Choi ,  Hyun-Jung Sung

IPC分类号： C07F5/02

CPC分类号： C07F5/025 ,  A61K31/69

摘要： The present invention relates to a novel tricyclic benzoxaborole derivative, a preparation method thereof, and use of antibiotics pharmaceutical composition including the same as an active ingredient.

摘要翻译： 本发明涉及一种新型的三环苯并恶灵衍生物及其制备方法，以及使用包含其的活性成分的抗生素药物组合物。

公开(公告)号：US20130296571A1

公开(公告)日：2013-11-07

申请号：US13989407

申请日：2010-11-24

申请人： Miwon Son ,  Tae Ho Lee ,  Sang Zin Choi ,  Nam Joon Baek ,  Kang Ro Lee ,  Ki Hyun Kim ,  Soon Hoe Kim

发明人： Miwon Son ,  Tae Ho Lee ,  Sang Zin Choi ,  Nam Joon Baek ,  Kang Ro Lee ,  Ki Hyun Kim ,  Soon Hoe Kim

IPC分类号： C07D221/18

CPC分类号： C07D221/18

摘要： The present invention relates to a novel quinoline derivative compound, an optical isomer thereof, a pharmaceutically acceptable salt thereof, and a hydrate or a solvate thereof. The novel quinoline derivative compound, the optical isomer thereof, the pharmaceutically acceptable salt thereof, and the hydrate or the solvate thereof accelerates gastrointestinal movement, and thus can effectively prevent or treat gastrointestinal motility disorders.

摘要翻译： 本发明涉及一种新的喹啉衍生物化合物，其旋光异构体，其药学上可接受的盐及其水合物或溶剂合物。 新型喹啉衍生物，其旋光异构体，其药学上可接受的盐及其水合物或溶剂合物加速胃肠运动，从而可有效预防或治疗胃肠蠕动障碍。

公开(公告)号：US11992562B2

公开(公告)日：2024-05-28

申请号：US16957774

申请日：2018-11-07

申请人： DONG-A ST CO., LTD. ,  KM TRANSDERM LTD.

发明人： Sun-Woo Jang ,  Chang-Yell Shin ,  Jeong-Soo Kim ,  Hae-Sun Kim ,  Kwang-Ho Cha ,  Hyun-Jung Kim ,  Masaoki Goto

IPC分类号： A61K9/70 ,  A61F13/02 ,  A61K31/445 ,  A61K47/12 ,  A61K47/14 ,  A61K47/32 ,  A61K47/44 ,  B29D7/01 ,  B29K71/00 ,  B29L31/00

CPC分类号： A61K9/7084 ,  A61F13/0276 ,  A61K31/445 ,  A61K47/12 ,  A61K47/14 ,  A61K47/32 ,  A61K47/44 ,  A61F2013/0296 ,  B29D7/01 ,  B29K2071/02 ,  B29L2031/753

摘要： A percutaneous absorption preparation is disclosed. The percutaneous absorption preparation contains donepezil for treatment of dementia, wherein the preparation includes: (a) donepezil or its pharmaceutically acceptable salt as active component, (b) propylene glycol monocaprylate as solubilizer, and (c) styrene-isoprene-styrene block copolymer (“SIS”) as adhesive. The percutaneous absorption preparation has low skin irritation and high skin penetration.